高级检索

替戈拉生与艾司奥美拉唑对反流性食管炎的疗效比较及治疗失败的影响因素分析

Efficacy of tegoprazan versus esomeprazole in treatment of reflux esophagitis and analysis of influencing factors for treatment failure

    摘要
  • 摘要:
    目的 比较替戈拉生与艾司奥美拉唑对反流性食管炎(RE)的疗效, 并分析治疗失败的影响因素。
    方法 选取120例RE患者作为研究对象, 采用随机数字表法分为对照组(艾司奥美拉唑治疗)和观察组(替戈拉生治疗), 每组60例。比较2组患者的临床疗效和胃镜疗效, 依据胃镜评估结果分为失败组26例和成功组94例。收集并比较失败组与成功组患者的临床资料, 采用多因素Logistic回归分析筛选RE患者治疗失败的影响因素。
    结果 观察组临床总有效率为93.33%(56/60), 高于对照组的76.67%(46/60), 差异有统计学意义(P < 0.05);观察组胃镜下总有效率为88.33%(53/60), 高于对照组的68.33%(41/60), 差异有统计学意义(P < 0.05)。失败组体质量指数(BMI)>28 kg/m2、糖尿病、有家族史、幽门螺杆菌(Hp)感染、胃食管反流病洛杉矶分级(LA分级) C~D级、使用艾司奥美拉唑治疗患者占比均高于成功组, 差异有统计学意义(P < 0.05)。多因素Logistic回归分析显示, BMI>28 kg/m2、合并糖尿病、LA分级C~D级、使用艾司奥美拉唑治疗均为RE患者治疗失败的独立危险因素(P < 0.05)。
    结论 替戈拉生治疗RE临床效果显著, 疗效优于艾司奥美拉唑; BMI>28 kg/m2、合并糖尿病、LA分级C~D级、使用艾司奥美拉唑治疗均为RE患者治疗失败的危险因素。

     

    Abstract:
    Objective To compare the efficacy of tegoprazan and esomeprazole in treatment of reflux esophagitis (RE) and analyze the influencing factors for treatment failure.
    Methods A total of 120 RE patients were selected as study subjects and divided into control group (treated with esomeprazole) and observation group (treated with tegoprazan) using random number table method, with 60 cases in each group. The clinical efficacy and gastroscopic efficacy of the two groups were compared. Based on the gastroscopic assessment results, the patients were divided into failure group (26 cases) and success group (94 cases). The clinical data of the failure group and the success group were collected and compared. Multivariate Logistic regression analysis was used to screen the influencing factors for treatment failure in RE patients.
    Results The total clinical effective rate in the observation group was 93.33% (56/60), which was higher than 76.67%(46/60) in the control group (P < 0.05). The total effective rate under gastroscopy in the observation group was 88.33%(53/60), which was higher than 68.33%(41/60) in the control group, and the difference was statistically significant (P < 0.05). The proportions of patients with body mass index (BMI)>28 kg/m2, diabetes, a family history, Helicobacter pylori (Hp) infection, Los Angeles classification (LA classification) of gastroesophageal reflux disease (GERD) grade C to D, and treated with esomeprazole in the failure group were all higher than those in the success group, and the differences were statistically significant (P < 0.05). Multivariate Logistic regression analysis showed that BMI>28 kg/m2, concomitant diabetes, LA classification grade C to D, and treatment with esomeprazole were all independent risk factors for treatment failure in RE patients (P < 0.05).
    Conclusion Tegoprazan has a significant clinical effect in treatment of RE, and its efficacy is superior to that of esomeprazole. BMI>28 kg/m2, concomitant diabetes, LA classification grade C to D, and treatment with esomeprazole are all risk factors for treatment failure in RE patients.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回